10 November 2026

Sofdra® receives the International Hyperhidrosis Society Seal of Recognition™

PHOENIX, USA – 10 November 2026: Commercial dermatology company, Botanix Pharmaceuticals Limited (ABN 70 009 109 755) (ASX:BOT, "Botanix" or "the Company"), is pleased to announce that *Sofdra*® (sofpironium) topical gel, 12.45% is a recipient of the International Hyperhidrosis Society Seal of Recognition™. This is the first time in 20 years that recognition has been awarded.

The International Hyperhidrosis Society (IHhS) is a US-based non-profit organisation dedicated to people living with hyperhidrosis, or excessive sweating. With this award, *Sofdra*® is 'Recognized by the International Hyperhidrosis Society for Research & Rigor in Helping Combat Excessive Sweating™.' The award highlights products, devices, and procedures validated by strong scientific and clinical evidence, rigorous testing, demonstrated efficacy and tolerability, and responsible marketing communications.

The recognition arrives at the start of Hyperhidrosis Awareness Month. IHhS has led the awareness month each November to spotlight a common medical condition that profoundly affects a patient's quality of life.[1] Hyperhidrosis can affect the face, hands, feet, underarms and other areas of the body. It affects more than 16 million Americans, yet many people do not recognise it as a medical condition, and only around half raise it with their doctor.

Once again, Botanix is supporting Hyperhidrosis Awareness Month with increased promotion in dermatology offices designed to raise awareness of primary axillary hyperhidrosis (excessive underarm sweating) and *Sofdra.* New materials placed in physicians' waiting areas and exam rooms are designed to help patients self-identify their condition and prompt conversations about primary axillary hyperhidrosis between physicians and patients.

Botanix Chief Executive Officer Dr Howie McKibbon said:

'We are honoured that *Sofdra* is a Recipient of the IHhS Seal of Recognition™ for Research & Rigor in Helping Combat Excessive Sweating™. IHhS has long been the champion of people living with hyperhidrosis, so this recognition carries real meaning for Botanix.

'Hyperhidrosis Awareness Month is a reminder that excessive sweating is a medical condition, not a personal characteristic. Too many people live with it and go untreated. If this month encourages even a few more people to talk to their doctor, that is a win for the whole community.'

Release authorised by

Vince Ippolito
Executive Chairman

[1] Dolittle, et al, 2016, Hyperhidrosis: an update on prevalence and severity in the United States, Archives of Dermatology Research.

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Phoenix (US), which has received FDA approval for *Sofdra*, its product for the treatment of primary axillary hyperhidrosis. *Sofdra* is the first and only new chemical entity approved by FDA to treat primary axillary hyperhidrosis and presents a novel, safe and effective solution for patients who have lacked treatment options for this socially challenging medical condition.

To learn more, please visit: www.botanixpharma.com

For more information, please contact:

General enquiries
Botanix Pharmaceuticals
Corporate Communications
P: +61 8 6285 0083
info@botanixpharma.com

Investor and Media Relations
Jane Morgan Management
Wilamina Russo
P: +61 450 646 609
wr@janemorganmanagement.com.au

Cautionary Note on Forward-Looking Statements

Forward-looking statements can generally be identified by the use of forward-looking words such as, "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "propose", "will", "believe", "forecast", "estimate", "target" "outlook", "guidance" and other similar expressions and include, but are not limited to, plans and prospects for the Company, the Company's strategy, future operations, the expected timing and/or results of regulatory approvals and prospects of commercialising product candidates or research collaborations with its partners, including in Japan, the outcome and effects of *Sofdra* and the market for *Sofdra*. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements. The forward-looking statements contained in this announcement are not indications, guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Botanix, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. Investors should consider the forward-looking statements contained in this announcement in light of those disclosures and not place undue reliance on such statements. Except as required by law or regulation, Botanix undertakes no obligation to update forward-looking statements.